The American Board of Allergy and Immunology’s (ABAI) Maintenance of Certification (MOC) program offers evidence of highly qualified physicians who use best practices and evidence-based standards for care. Linking the educational content of the ACAAI Annual Scientific Meetings to the MOC program is one way the College helps its members provide ABAI with evidence of their commitment to lifelong learning.
IMPORTANT: ABAI’s MOC program requires diplomates to obtain a minimum of 25 CME credits in allergy and immunology each year. CME credits for the Annual Meeting can be used to satisfy this requirement.
Additionally, the ABAI recommends that 6 of the 25 credits be designated as self-assessment (MOC Part II) credit. With the approval of ABAI, the College has designated eight sessions at the meeting for MOC self-assessment credit.
In order to earn MOC self-assessment credit at designated sessions:
You must be currently enrolled in the ABAI’s MOC program.
You must attend the entire designated session.
You must fully complete a paper form, including answering all pre- and post-test questions, providing a full name and ACAAI badge ID number.
Forms must be legible in order to receive credit.
ACAAI will submit the required reports that include MOC self-assessment credits to the ABAI. ABAI will enter the MOC self-assessment credits onto the ABAI web portal page. The amount of MOC self-assessment credit earned is always equal to the amount of AMA PRA Category 1 Credit™ claimed for the session. (Partial self-assessment credit is not available.) Faculty cannot earn CME or MOC self-assessment credit for their own presentations.
Ultimately, CME activities for which MOC self-assessment credit is awarded may be cross-referenced to the ABAI examination content outline, available on the ABAI website. Details of the six Core Competencies are also located on the ABAI website. The six Core Competencies are: Patient Care and Procedural Skills; Medical Knowledge; Practice-based Learning and Improvement; Interpersonal and Communication Skills; Professionalism; and System-based Practice.
There remains extensive debate regarding the definition of mastocytosis and MCAS. This session will clarify the diagnostic criteria and outline treatment possibilities.
1:30 PM
-
1:35 PM
Welcome and Introductions
1:35 PM
-
2:00 PM
History and Associated Diseases
2:00 PM
-
2:25 PM
Laboratory Evaluation: Develop a Diagnostic Treatment Plan
Room: Auditorium (2nd Floor), Hynes Convention Center
Data and guidelines supporting early allergen (specifically peanut) introduction are new. These recommendations evolve former practice that supported either delay in peanut introduction (AAP, 2000), and then equipoise/no benefit in delay in the timing (AAP, 2008 and AAAAI 2013). Because the guidelines are new, there are no practical recommendations as to how to implement the new policy nor how to integrate an anticipated influx of referrals of high-risk infants requiring in-office peanut introduction into the office-based practice.
11:00 AM
-
11:05 AM
Welcome and Introductions
11:05 AM
-
11:30 AM
The Scope of Dietary and Health Benefits Related to Early Peanut Introduction
Room: Auditorium (2nd Floor), Hynes Convention Center
There are multiple biologics that have been approved for asthma. This session will explore the patient profiles that may predict a response to each agent.
Supported by an independent educational grant from GlaxoSmithKline
This new format will provide information regarding expected outcomes when alternative non-pharmacologic compounds are used and will explore the positive and negative effects of these supplements.
Room: Auditorium (2nd Floor), Hynes Convention Center
Many primary immunodeficiencies present with signs and symptoms of immune dysregulation. We will highlight national data on non-infectious complications of PID and discuss the evaluation of patients. We will also present current information on the use of biologicals to treat specific immune deficiencies, as well as advances in this area.
3:30 PM
-
3:35 PM
Welcome and Introductions
3:35 PM
-
4:00 PM
What We Know: Data From USIDNet on the Frequency of Non-infectious Complications of PID
4:00 PM
-
4:25 PM
What We Need to Know: Evaluation of PID Patients With Immune Dysregulation
4:25 PM
-
4:50 PM
Where Are We Going? Personalized Therapy for Monogeneic Immune Deficiency with Immune Dysregulation
There remains extensive debate regarding the definition of mastocytosis and MCAS. This session will clarify the diagnostic criteria and outline treatment possibilities.
